Setmelanotide Dosage Guide

The FDA-approved MC4R-agonist peptide (Imcivree). Subcutaneous titration to 3 mg, the rare genetic conditions it is approved for, the Phase 3 trials, and safety.

Compiled by PeptideWiki Editorial Team·Last reviewed June 23, 2026

What Is Setmelanotide?

An approved rare-disease medicine: Setmelanotide (Imcivree) is FDA-approved, but only for specific genetic forms of severe obesity, not for general weight loss. This guide explains the approved dosing and, importantly, who it is and is not for.

Setmelanotide, sold under the brand name Imcivree, is a peptide medicine given as a once-daily injection under the skin. It activates MC4R, a receptor in the brain that signals fullness. Unlike most compounds covered here, it is a genuine peptide and an FDA-approved drug.

It was designed for people whose obesity is driven by a broken hunger-control pathway in the brain. In those people, the natural signal that tells the brain you are full is missing or weak, causing constant hunger and severe obesity from early childhood. Setmelanotide replaces that signal directly.

Key Characteristics:

MC4R-agonist peptide: activates the brain's MC4R fullness receptor, more strongly than the body's own signal
FDA-approved (Imcivree): a regulated medicine, not a research-only compound
Rare-disease indications: approved for POMC, PCSK1, and LEPR deficiency, and Bardet-Biedl syndrome
Once-daily injection: given subcutaneously, titrated to a maximum of 3 mg per day
Skin pigment effect: commonly darkens skin and moles, an expected effect of the pathway
Not for general obesity: not approved or tested in people with a normal hunger pathway

For the full mechanism and research, see our Setmelanotide profile.

Who Setmelanotide Is Actually For

This is the single most important point about setmelanotide, and it is often blurred in marketing. It is a targeted treatment for specific rare genetic conditions, not a general weight-loss drug.

Approved For	What It Is
POMC or PCSK1 deficiency	Genetic defects that stop the body making the natural MC4R-activating signal
LEPR deficiency	A defect in the leptin receptor, upstream in the same hunger pathway
Bardet-Biedl syndrome	A rare genetic syndrome that impairs the same pathway and causes severe obesity
Hypothalamic obesity	Acquired damage to the brain region that controls hunger (a later approval)

If your hunger pathway is intact, which is the case for the large majority of people with overweight or obesity, setmelanotide has not been shown to produce the results seen in the genetic trials, and it is not approved for that use. For common obesity, the GLP-1 medicines such as Semaglutide and Tirzepatide have far more evidence.

Verified sources for Setmelanotide

These vendors are vetted by PeptideWiki for purity testing and COA transparency.

SwissChemsThird-party tested research peptides10% off

SwissChems10% off

Limitless BiotechPremium nootropics & research peptides15% off

Limitless Biotech15% off

CH PeptidesResearch-grade peptides with COA transparency10% off

CH Peptides10% off

View all vendor deals·Affiliate links. Commission at no extra cost.

How Setmelanotide Dosage Is Determined

Setmelanotide dosing comes from the Phase 3 trials that supported its approval, all conducted in the rare genetic obesity populations.

Trial	Population	≥10% Weight Loss at ~1 Year
Phase 3 (2020)	POMC deficiency	80% (8 of 10)
Phase 3 (2020)	LEPR deficiency	45% (5 of 11)
Phase 3 (2022)	Bardet-Biedl syndrome	~32% (aged 12 and older, at 52 weeks)

Alongside weight loss, the trials showed large reductions in hunger scores, often the more meaningful change for patients whose defining symptom is relentless hunger. The maximum dose across the trials was 3.0 mg once daily.

Dosing in this guide reflects the approved label and the Phase 3 trials. It should be used under specialist supervision for an approved indication.

Setmelanotide Dosing & Titration

Setmelanotide is started low and increased gradually to limit nausea and other early effects, up to a maximum of 3.0 mg once daily by subcutaneous injection. The exact starting dose depends on age.

Step	Adult Dose	Purpose
Start	2.0 mg daily	Assess tolerance over the first 2 weeks
Increase	3.0 mg daily	If tolerated and more effect is needed
Maximum	3.0 mg daily	The ceiling dose. Do not exceed

Children use lower starting doses based on age and weight, and titrate under specialist care. The 3 mg maximum applies across ages. Never start at the maximum dose.

Preparation

The approved product, Imcivree, comes as a ready-to-use solution, so no mixing is required. Material obtained as a research compound may instead be a freeze-dried powder that needs reconstitution with bacteriostatic water first.

Approved vs research material: the FDA-approved solution is prepared to a known strength. Research-sourced powder has no guaranteed strength or purity, and reconstitution errors change the dose you receive. The approved product under medical supervision is the only validated path.

Steps (for a powder form)

Check the Form

Approved Imcivree comes as a ready-to-use solution in a vial, so no mixing is needed. Research-sourced setmelanotide may instead come as a freeze-dried powder that requires reconstitution, the steps below cover that case.

Wash Hands & Prepare

Wash hands thoroughly. Lay out the vial, bacteriostatic water (for a powder), an insulin syringe, and alcohol swabs on a clean surface.

Swab the Stoppers

Wipe the rubber stoppers of both the setmelanotide vial and the water vial with alcohol pads and let them air-dry for 10 to 15 seconds.

Add Water Gently (Powder Only)

Draw your chosen volume of bacteriostatic water and inject it slowly down the inside wall of the vial, not directly onto the powder. Let it dissolve without shaking.

Inspect the Solution

The solution should be clear and colorless. Do not use it if it is cloudy, discolored, or has particles.

Label & Refrigerate

Write the date and concentration on the vial. Store refrigerated at 2 to 8 degrees Celsius and protect from light.

Setmelanotide Injection Guide

Route: subcutaneous, into the fat just under the skin
Sites: lower abdomen (2 to 3 inches from the navel), upper thigh, or back of the upper arm. Rotate sites daily
Frequency: once daily, same time each day, usually morning
Technique: clean the site, pinch a fold of skin, insert at a 45 to 90 degree angle, inject slowly, then dispose of the needle in a sharps container
Half-life: about 11 hours, which is why it is a daily injection
Missed dose: resume the next day at the usual time rather than doubling up

Watch the injection sites and skin: rotate sites to protect the fat tissue, and because setmelanotide affects pigment, note any darkening or new moles to raise with your clinician.

Setmelanotide vs GLP-1 Weight-Loss Drugs

Setmelanotide is often searched alongside the GLP-1 drugs, but they serve different purposes. The table makes the distinction clear.

Feature	Setmelanotide	Semaglutide / Tirzepatide
Target	MC4R (melanocortin pathway)	GLP-1 (and GIP) gut hormone
Approved for	Rare genetic obesity	Common obesity and type 2 diabetes
Frequency	Once daily injection	Once weekly injection
Signature side effect	Skin and mole darkening	Gastrointestinal effects
Right candidate	Confirmed genetic pathway defect	General overweight or obesity

For the broadly-used options, see our Semaglutide Dosage Guide and Tirzepatide Dosage Guide.

Setmelanotide Treatment Duration

For the genetic conditions it treats, setmelanotide is a long-term therapy. The underlying defect does not resolve, so the benefit depends on continued use, and the trials ran for a year or more.

Phase	Timing	What Happens
Titration	First weeks	Dose is raised gradually, hunger usually drops early
Active treatment	Up to 1 year	Most weight loss occurs. Effectiveness is reassessed at about 1 year
Ongoing	Long-term	Continued to maintain benefit, since the genetic defect persists

Reassessment at one year: the label directs stopping treatment if a patient has not lost meaningful weight after about a year, since continued use without benefit is not justified.

Safety, Side Effects & Cautions

Common Side Effects

Side Effect	Notes
Skin and mole darkening	Expected effect of the pathway, reported in most participants. Needs dermatology monitoring
Injection-site reactions	Very common. Rotate sites
Nausea and vomiting	More common early. Eased by gradual titration
Sexual effects	Spontaneous erections in males and sexual adverse events in females reported
Mood changes	Depression and suicidal ideation were monitored. Watch for these

Important Cautions

Skin checks: a full skin and mole exam before starting and during treatment, because the drug affects pigment cells
Mental health: monitor for new or worsening depression or suicidal thoughts
Pregnancy and breastfeeding: not recommended, weight loss provides no benefit during pregnancy
Specialist supervision: intended for use under a clinician experienced with these rare conditions

Approved and monitored: because setmelanotide is an approved drug, it has a defined safety profile and label, an advantage over unregulated research compounds. That safety profile still includes effects, like pigment change, that need active monitoring.

Common Setmelanotide Mistakes

Avoid these errors with setmelanotide:

Assuming it is a general weight-loss drug: Setmelanotide is approved and effective for specific rare genetic obesity conditions. It was not tested in, and is not approved for, common obesity. Expecting trial-level results without one of these conditions is the central misunderstanding.

Skipping titration: Starting at the full 3 mg dose rather than titrating up increases nausea and other early side effects. The dose is raised gradually based on response and tolerance.

Ignoring skin and mole changes: Darkening of skin and moles is an expected effect, but new or changing moles still need a dermatologist's eye. A skin exam before and during treatment is part of safe use, not optional.

Using it without genetic or specialist confirmation: Approval is tied to confirmed genetic diagnoses and specialist supervision. Using it on the assumption of a melanocortin-pathway problem, without confirmation, means taking an injectable drug with no expectation of benefit.

Not monitoring mood: Depression and suicidal ideation were monitored in the trials. Anyone using setmelanotide should watch for mood changes and seek help promptly if they occur.

Frequently Asked Questions

Key Takeaways

Setmelanotide (Imcivree) is an FDA-approved MC4R-agonist peptide, a real medicine, not a research-only compound
It is for rare genetic obesity, POMC, PCSK1, or LEPR deficiency, Bardet-Biedl syndrome, and hypothalamic obesity, not general weight loss
Dose is titrated to a maximum of 3 mg once daily by subcutaneous injection
It worked well in the genetic trials, with the majority of patients losing meaningful weight and hunger
Skin and mole darkening is expected and requires dermatology monitoring
For common obesity, the GLP-1 drugs have far more evidence

This article is for educational and informational purposes only. See our Disclaimer.

References

Clement K, et al. “Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: phase 3 trials.” Lancet Diabetes Endocrinol. 2020;8(12):960-970. PubMed
Haqq AM, et al. “Efficacy and safety of setmelanotide in patients with Bardet-Biedl syndrome and Alstrom syndrome: a phase 3 trial.” Lancet Diabetes Endocrinol. 2022;10(12):859-868. PubMed
Collet TH, et al. “Evaluation of a melanocortin-4 receptor (MC4R) agonist (Setmelanotide) in MC4R deficiency.” Mol Metab. 2017;6(10):1321-1329. PubMed
Kuhnen P, et al. “Quality of life outcomes in two phase 3 trials of setmelanotide in patients with obesity due to LEPR or POMC deficiency.” Orphanet J Rare Dis. 2022;17(1):38. PubMed

Next Steps

Continue your research with these resources.

Semaglutide Dosage Guide

The widely-used GLP-1 option for common obesity, a different pathway from setmelanotide.

Read Guide

Best Peptides for Weight Loss

How setmelanotide fits among the broader weight-management research landscape.

Read Article

Peptide Directory

Browse every compound with research summaries and evidence ratings.

Open Directory